Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Efficacy of glucosamine, chondroitin sulfate may depend on level of osteoarthritis pain

23.02.2006


Most participants in GAIT study saw little relief



The popular dietary supplements glucosamine and chondroitin sulfate proved no better than a placebo in relieving osteoarthritis knee pain in most participants of a major national trial. But the study, published in the Feb. 23 issue of the New England Journal of Medicine, also showed a smaller subgroup of trial patients with moderate to severe osteoarthritis knee pain taking the combination of the two supplements experienced significant pain relief.

"For the study population as a whole, supplements were found to be ineffective," said rheumatologist Daniel O. Clegg, M.D., professor of medicine at the University of Utah School of Medicine, chief of rheumatology at the George E. Wahlen Veterans Affairs Medical Center in Salt Lake City, and principal investigator for the national trial. "An exploratory analysis suggested, however, that the combination of glucosamine and chondroitin sulfate might be effective in patients who suffer from moderate to severe osteoarthritis knee pain."


Glucosamine, an amino sugar the body produces and distributes in cartilage and other connective tissue, and chondroitin sulfate, a complex carbohydrate that helps cartilage retain water, have become popular remedies among osteoarthritis sufferers in recent decades. But evidence of the supplements’ ability to control pain had been anecdotal.

The five-year, $12.5 million Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) was designed to rigorously assess the efficacy and safety of glucosamine and chondroitin sulfate, taken either separately or in combination. Nearly 1,600 patients with painful knee osteoarthritis were enrolled in the trial and randomly assigned to take placebo, celecoxib (a widely prescribed arthritis pain drug), glucosamine, chondroitin sulfate, or a combination of the two supplements for 24 weeks. Of the 1,583 study patients, 78 percent were in the mild knee pain subgroup and the remaining 22 percent were in the moderate to severe subgroup.

Celecoxib served as the study’s positive control because it is an approved osteoarthritis pain drug and participants would be expected to respond in a predictable way.

For all trial patients, celecoxib proved most effective in providing significant pain relief, with a 70 percent response rate, compared to 64 percent for glucosamine and 65 percent for chondroitin sulfate. Taken in combination, the supplements provided significant relief for 66 percent of patients who receive them. The response rate in those who took placebo was 60 percent.

In participants in the mild knee pain subgroup, celecoxib proved the most effective, significantly improving pain relief for 70 percent of those who took it, compared to nearly 64 percent for glucosamine, 67 percent for chondroitin sulfate, and 63 percent for the combination of the two. Placebo produced a 62 percent response rate for people with mild pain.

"As we expected, patients who took celecoxib showed significant improvement in pain relief," Clegg said.

In patients in the moderate-to-severe knee pain subgroup, however, the combination of the two supplements appeared to be more effective than placebo, significantly reducing pain in 79 percent of those who received it. This is compared with 69 percent who took celecoxib and 54 percent who took placebo. Because only 22 percent of the trial participants were in the moderate-to-severe subgroup, this result should be considered preliminary and further study will be required to confirm these results, according to Clegg.

Conducted at 16 U.S. academic rheumatology centers, the study was funded by the National Center for Complementary and Alternative Medicine (NCCAM) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), components of the National Institutes of Health.

Study participants were required to have both pain and X-ray evidence of osteoarthritis in their knees. They were evaluated at the beginning of the trial and at weeks four, eight, 16, and 24, with a positive treatment response defined as a 20 percent or greater decrease in knee pain compared to the start of the study.

More than 20 million Americans have osteoarthritis. Oral doses of glucosamine and chondroitin sulfate, derived from animal products, have become popular with arthritis sufferers in the past 20 or so years.

"I urge people with osteoarthritis to follow a comprehensive plan for managing their arthritis pain. Developing and maintaining a healthy lifestyle is key to the successful management of osteoarthritis--eat right, exercise regularly, lose excess weight, and consider the use of medications based on your degree of pain," Clegg said.

In a second part of the study, Clegg and other researchers will track whether taking glucosamine and chondroitin sulfate alone and in combination affects progression of knee osteoarthritis. All participants in the second part of the study had a knee X-ray at the beginning of the trial and will be imaged again at years one and two. X-rays will be compared and evaluated to assess whether these supplements affect progression of osteoarthritis. Results of the second part of the study are expected in about a year.

Phil Sahm | EurekAlert!
Further information:
http://www.hsc.utah.edu

More articles from Studies and Analyses:

nachricht A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg

nachricht Urbanization to convert 300,000 km2 of prime croplands
27.12.2016 | Mercator Research Institute on Global Commons and Climate Change (MCC) gGmbH

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

Im Focus: Newly proposed reference datasets improve weather satellite data quality

UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration

"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...

Im Focus: Repairing defects in fiber-reinforced plastics more efficiently

Fiber-reinforced plastics (FRP) are frequently used in the aeronautic and automobile industry. However, the repair of workpieces made of these composite materials is often less profitable than exchanging the part. In order to increase the lifetime of FRP parts and to make them more eco-efficient, the Laser Zentrum Hannover e.V. (LZH) and the Apodius GmbH want to combine a new measuring device for fiber layer orientation with an innovative laser-based repair process.

Defects in FRP pieces may be production or operation-related. Whether or not repair is cost-effective depends on the geometry of the defective area, the tools...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Solar Collectors from Ultra-High Performance Concrete Combine Energy Efficiency and Aesthetics

16.01.2017 | Trade Fair News

3D scans for the automotive industry

16.01.2017 | Automotive Engineering

Nanoparticle Exposure Can Awaken Dormant Viruses in the Lungs

16.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>